Activity: Other
Location: Loos, France
Contract type: Internship - Stage

Contribute to an exciting mission
What will your daily life look like?

Project: Study and validation of new bacterial strains of interest in breadmaking, plant biocontrol & biostimulation and human and animal nutrition & health.

Within Lesaffre International's Bacteria platform of the R&D center, you will be more particularly attached to the Microbiology team.

Main missions:

• You ensure the development and validation of methods for studying bacterial strains from the Lesaffre R&D collection, from setting up experiments to writing results and protocols. The techniques used include microorganism culture, genomic sequence analysis, the use of molecular biology tools (DNA extraction, qPCR) and microorganism activity analysis using classical and/or high throughput setups.

• You may participate in the Scientific and Technological Watch on the field related to the microorganisms of interest as well as the research of technical solutions (methodology, protocols …).

Make a personal impact
That makes you the ideal candidate

Training: BSc or MSc internship in Microbiology / Biotechnology.

• You are recognized for your capacities of analysis and synthesis, your curiosity, relational and editorial qualities.

• You are willing to work in English. French is a plus.

Let’s take on tomorrow’s challenges together

Acteur mondial de référence dans le domaine des levures et de la fermentation, Lesaffre conçoit, produit et apporte des solutions innovantes pour la panification, le goût & plaisir alimentaire, le bien-être & la santé et la biotechnologie.

Groupe familial, né dans le Nord de la France en 1853, aujourd’hui multi-local et pluriculturel, Lesaffre s’engage à entreprendre avec confiance pour mieux nourrir et protéger la planète.

Proche de ses clients et de ses partenaires, Lesaffre emploie 9500 collaborateurs répartis dans plus de 70 filiales implantées dans une quarantaine de pays.

Lesaffre réalise un chiffre d’affaires 2 milliards d’euros dont plus de 40% dans les pays émergents.